Literature DB >> 10463134

Attenuation by acetyl-L-carnitine of neurological damage and biochemical derangement following brain ischemia and reperfusion.

M Calvani1, E Arrigoni-Martelli.   

Abstract

Alterations in brain metabolism after ischemia and reperfusion are described herein. Several roles played by carnitine and acetylcarnitine can be of particular relevance in counteracting these brain metabolism alterations. The effects of acetylcarnitine in several experimental models of brain ischemia in rats are described. The data obtained show that acetylcarnitine can have significant clinical neuroprotective effects when administered shortly after the onset of focal or global cerebral ischemia. In the canine cardiac arrest model, acetylcarnitine improved the postischemic neurological outcome and tissue levels of lactate and pyruvate were normalized. A trend toward reversal of pyruvate dehydrogenase inhibition in acetylcarnitine-treated dogs was also observed. The immediate postischemic administration of acetylcarnitine prevents free radical-mediated protein oxidation in the frontal cortex of dogs submitted to cardiac arrest and resuscitation. The transfer of the acetyl group to coenzyme A (CoA) to form acetyl-CoA as the primary source of energy is a plausible mechanism of action of acetylcarnitine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10463134

Source DB:  PubMed          Journal:  Int J Tissue React        ISSN: 0250-0868


  16 in total

Review 1.  Acetyl-L-carnitine in HIV-associated antiretroviral toxic neuropathy.

Authors:  Mike Youle
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 2.  Tissue damage and oxidant/antioxidant balance.

Authors:  Abdullah Kisaoglu; Bunyamin Borekci; O Erkan Yapca; Habib Bilen; Halis Suleyman
Journal:  Eurasian J Med       Date:  2013-02

Review 3.  Interplay between NAD+ and acetyl‑CoA metabolism in ischemia-induced mitochondrial pathophysiology.

Authors:  Nina Klimova; Aaron Long; Susana Scafidi; Tibor Kristian
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-09-24       Impact factor: 5.187

Review 4.  Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity.

Authors:  V Calabrese; G Scapagnini; A M Giuffrida Stella; T E Bates; J B Clark
Journal:  Neurochem Res       Date:  2001-06       Impact factor: 3.996

5.  Acetyl-L-carnitine as an adjunctive therapy in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a placebo-controlled trial.

Authors:  Seyed-Hesameddin Abbasi; Shahram Heidari; Mohammad-Reza Mohammadi; Mina Tabrizi; Ali Ghaleiha; Shahin Akhondzadeh
Journal:  Child Psychiatry Hum Dev       Date:  2011-06

Review 6.  Prevention of ammonia and glutamate neurotoxicity by carnitine: molecular mechanisms.

Authors:  Marta Llansola; Slaven Erceg; Mariluz Hernández-Viadel; Vicente Felipo
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

7.  Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine.

Authors:  V Calabrese; G Scapagnini; A Ravagna; R Bella; D A Butterfield; M Calvani; G Pennisi; A M Giuffrida Stella
Journal:  Neurochem Res       Date:  2003-09       Impact factor: 3.996

Review 8.  Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders.

Authors:  Carmen Mingorance; Rosalía Rodríguez-Rodríguez; María Luisa Justo; María Alvarez de Sotomayor; María Dolores Herrera
Journal:  Vasc Health Risk Manag       Date:  2011-03-28

9.  Hypoxia-induced lipid peroxidation in rat brain and protective effect of carnitine and phosphocreatine.

Authors:  Hana Rauchová; Jitka Koudelová; Zdenĕk Drahota; Jindrich Mourek
Journal:  Neurochem Res       Date:  2002-09       Impact factor: 3.996

Review 10.  Astrocyte mitochondrial mechanisms of ischemic brain injury and neuroprotection.

Authors:  Linda Bambrick; Tibor Kristian; Gary Fiskum
Journal:  Neurochem Res       Date:  2004-03       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.